Abstract

Purpose To investigate the value of diffusion-weighted MR imaging (DWI) in detection of cervical cancer, and to determine the diagnostic accuracy of apparent diffusion coefficient (ADC) values for evaluating cervical cancer before and after chemoradiotherapy. Materials and methods Thirty-three patients with cervical squamous carcinoma and 20 patients with other pelvic abnormalities underwent diffusion-weighted imaging (DWI) in addition to routine MR imaging. The ADC values of normal cervical tissue, cervical area before and after chemoradiotherapy were measured and compared. Receiver operating characteristic (ROC) analysis was employed to investigate whether ADC values could help in discrimination among normal cervical tissue, cervical cancer before and after therapy, and to obtain the optimal ADC threshold value. Results Cervical cancer lesion demonstrated obviously hyperintensity on DWI images. The mean ADC value of cervical carcinoma (1.110 ± 0.175 × 10 −3 mm 2/s) was significantly lower than that of normal cervical tissue (1.593 ± 0.151 × 10 −3 mm 2/s) ( P < 0.001). The mean ADC value of the cervical area in 22 patients treated by chemoradiotherapy (1.436 ± 0.129 × 10 −3 mm 2/s) was significantly higher than that before therapy (1.013 ± 0.094 × 10 −3 mm 2/s) ( P < 0.001). The difference of ADC values between normal cervical tissue and cervical area after therapy was statistically significant ( P < 0.01). The optimal ADC threshold values for distinguishing between normal cervical tissue and cervical carcinoma was 1.359 × 10 −3 mm 2/s, between cervical area before and after therapy was 1.255 × 10 −3 mm 2/s, between normal cervical tissue and cervical area after therapy was 1.525 × 10 −3 mm 2/s. The sensitivity and specificity were 100% and 84.8%, 95.5% and 100%, 70% and 81.8%, respectively. Conclusion DWI can be applied for the detection of cervical cancer because of its superior disease contrast with normal tissue. The measurement of the ADC values can be a useful tool to monitor the response to therapy for cervical carcinoma.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.